ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Promotion
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > IL-17A

IL-17A

概要

Name:Interleukin 17A
Target Synonym:Interleukin 17 (Cytotoxic T-Lymphocyte-Associated Serine Esterase 8),CTLA8,IL17A,Interleukin 17A,Cytotoxic T-Lymphocyte-Associated Antigen 8,Cytotoxic T-Lymphocyte-Associated Protein 8,CTLA-8,IL-17A,IL-17,IL17,Interleukin-17A
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:29
Lastest Research Phase:Approved

ライセンス

Project Name Modality Therapeutic Area Indications Stage Right Available
IL17A mAb Monospecific antibody Immunological disease Psoriasis,Axial spondyloarthritis SpA Phase III Global  (except China)

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
ILA-H5243 Human Human IL-17A / CTLA-8 Protein, His Tag (HPLC verified)
ILA-H5243-structure
ILA-H5243-sds
ILA-H5243-hplc
CEA-C092 Human ClinMax™ Human IL-17A / CTLA8 ELISA Kit
EP-140 Human IL-17A : IL-17RA [Biotinylated] Inhibitor Screening ELISA Kit
EP-139 Human IL-17A [Biotinylated] : IL-17RA Inhibitor Screening ELISA Kit
ILA-H5219 Human Human IL-17A / CTLA-8 Protein, premium grade
ILA-H5219-structure
ILA-H5219-sds
ILA-C52H7 Canine Canine IL-17A / CTLA-8 Protein, His Tag
ILA-C52H7-structure
ILA-C52H7-sds
ILA-C5249 Cynomolgus Cynomolgus IL-17A / CTLA-8 Protein, His Tag (MALS verified)
ILA-C5249-structure
ILA-C5249-sds
ILA-H82Q1 Human Biotinylated Human IL-17A / CTLA-8 Protein, His,Avitag™
ILA-H82Q1-structure
ILA-H82Q1-sds
CT8-M5240 Mouse Mouse IL-17A / CTLA-8 Protein, His Tag (MALS verified)
CT8-M5240-structure
CT8-M5240-sds
ACRO Quality

生物活性データの一部

ILA-H5219-Cell-based assay
IL-17A CELL

Human IL-17A, premium grade (Cat. No. ILA-H5219) stimulates proliferation of 293F-NFKB/luc-IL17-30 cell line. The specific activity of Human IL-17A, premium grade is > 1.00ⅹ10^7 IU/mg, which is calibrated against human IL-17 WHO International Standard (NIBSC code: 01/420) (QC tested).

Protocol
CT8-M5240-Cell-based assay
IL-17A CELL

Mouse IL-17A, His Tag (Cat. No. CT8-M5240) stimulates secretion of IL-6 by NIH-3T3 cells. The ED50 for this effect is 2.132-5.005 ng/mL.

Protocol
ILA-H5243-SPR
IL-17A SPR

Human IL-17 RA Protein, Fc Tag (Cat. No. ILA-H525f) captured on Protein A Chip can bind Human IL-17A Protein, His Tag (Cat. No. ILA-H5243) with an affinity constant of 0.360 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol
ILA-H82Q1-BLI
IL-17A BLI

Loaded Biotinylated Human IL17A, His,Avitag (Cat. No. ILA-H82Q1) on SA Biosensor, can bind Human IL-17 RA, His Tag (Cat. No. ILA-H5222) with an affinity constant of 18.8 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

Synonym Name

IL-17A,Interleukin-17A,CTLA-8,IL-17

Background

Interleukin-17A (IL17A) is also known as cytotoxic T-lymphocyte-associated antigen 8 (CTLA8),which is a proinflammatory cytokine produced by activated T cells. IL17A can regulate the activities of NF-kappaB and mitogen-activated protein kinases. Also,IL17A can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO).Furthermore,IL17A has been found both in glycosylated and nonglycosylated forms. High levels of IL-17 are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.

Clinical and Translational Updates

相関分子

IL-17 RA

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Virulizin Approved Aptose Virulizin, Virulizin-2 gamma Mexico Sarcoma, Kaposi; Melanoma; Carcinoma, Renal Cell; Colorectal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms null 1997-01-01 Carcinoma, Renal Cell; Stomach Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Sarcoma, Kaposi; Melanoma; Uterine Cervical Neoplasms Details
Ixekizumab LY-2439821 Approved Eli Lilly And Company 拓咨, Taltz EU Non-radiographic axial spondyloarthritis; Spondylitis, Ankylosing Eli Lilly And Company (Ireland) Ltd 2016-03-22 Non-radiographic axial spondyloarthritis; Depressive Disorder, Major; Pyoderma Gangrenosum; Spondylitis, Ankylosing; Spondylarthritis; Arthritis, Rheumatoid; Psoriasis; Arthritis, Psoriatic; Lichen Planus; Pemphigoid, Bullous; Pityriasis Rubra Pilaris; Plaque psoriasis Details
Secukinumab NVP-AIN-457; AIN-457; KB-03303A Approved Novartis Pharma Ag Cosentyx, 可善挺 United States Arthritis, Juvenile; Arthritis, Psoriatic Novartis Pharma Ag 2014-12-26 Uveitis; Polymyalgia Rheumatica; Graves Ophthalmopathy; Psoriasis; Hyperkeratosis, Epidermolytic; Tendinopathy; Arthritis, Psoriatic; Parapsoriasis; Lichen Planus; Asthma; Multiple Sclerosis; Hidradenitis Suppurativa; Arthritis; Inflammation; Ichthyosiform Erythroderma, Congenital; Plaque psoriasis; Dermatitis, Atopic; Gastroenteritis; Behcet Syndrome; Crohn Disease; Spondylarthropathies; Diabetes Mellitus, Type 1; Multiple Sclerosis, Relapsing-Remitting; Necrobiosis Lipoidica; Non-alcoholic Fatty Liver Disease; Giant Cell Arteritis; Inflammatory Bowel Diseases; Alopecia Areata; Pyoderma Gangrenosum; Lupus Erythematosus, Discoid; Non-radiographic axial spondyloarthritis; Spondylitis, Ankylosing; Ichthyosis; Rotator Cuff Injuries; Arthritis, Rheumatoid; Spondylarthritis; Netherton Syndrome; Lupus Nephritis; Ichthyosis, Lamellar; Arthritis, Juvenile Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
UCB-0159 UCB-0159 Phase 1 Clinical Ucb Sa Autoimmune Diseases Details
JNJ-63823539 JNJ-63823539 Phase 1 Clinical Janssen Global Services Llc Arthritis, Rheumatoid Details
Recombinant human IL-17A/F humanized antibody (Livzon Pharmaceutical Group) LZM－012; LZM012 Phase 2 Clinical Livzon Pharmaceutical Group Inc, Beijing Kanova Biomedical Technology Co Ltd Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis Details
IMU-935 IMU-935 Immunic Ag Details
JNJ-61178104 JNJ-61178104 Phase 1 Clinical Janssen Global Services Llc Autoimmune Diseases Details
Vunakizumab SHR-1314 Phase 3 Clinical Jiangsu Hengrui Medicine Co Ltd Spondylarthritis; Autoimmune Diseases; Spondylitis, Ankylosing; Graves Ophthalmopathy; Lupus Nephritis; Psoriasis; Graves Disease; Arthritis, Psoriatic; Plaque psoriasis Details
RO-7040547 RG-7990; BIT-7201A; RO-7040547 Genentech Inc, Novimmune Sa Details
CJM-112 CJM-112 Phase 1 Clinical Novartis Pharma Ag Acne Vulgaris; Triple Negative Breast Neoplasms; Multiple Sclerosis; Multiple Myeloma; Psoriasis; Colorectal Neoplasms; Asthma; Hidradenitis Suppurativa; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma Details
Recombinant anti-IL-17A humanized monoclonal antibody (Shanghai Junshi Biosciences) JS005 Phase 2 Clinical Shanghai Junshi Biosciences Co Ltd Non-radiographic axial spondyloarthritis; Spondylarthritis; Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis Details
CMAB-015 CMAB015; CMAB-015 Phase 1 Clinical Taizhou Mabtech Pharmaceutical Co Ltd Details
Secukinumab biosimilar (Bio-Thera Solutions) BAT-2306 Phase 3 Clinical Bio-Thera Solutions Ltd Autoimmune Diseases; Psoriasis; Plaque psoriasis Details
Isomyosamine MYMD-1 Phase 2 Clinical Mymd Pharmaceuticals Inc Depression; Anxiety; Hashimoto Disease; Coronavirus Disease 2019 (COVID-19); Healthy Aging; Inflammation Details
ZL-1102 ZL-1102; CB-001 Phase 1 Clinical Crescendo Biologics Ltd, Zai Lab (Shanghai) Co Ltd Psoriasis Details
Gumokimab AK-111 Phase 2 Clinical Zhongshan Akeso Biopharma Co Ltd Spondylitis, Ankylosing; Spondylarthritis; Psoriasis; Plaque psoriasis Details
Xeligekimab GR-1501 Phase 3 Clinical Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd, Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd Spondylarthritis; Lupus Nephritis; Psoriasis; Plaque psoriasis Details
QX002N QX-002N Phase 2 Clinical Qyuns Therapeutics Co Ltd Spondylitis, Ankylosing Details
HY-1770 HY-1770; HY1770; HT-17; HT17 Phase 1 Clinical Suzhou Pharmavan Co Ltd Dermatitis, Atopic; Plaque psoriasis Details
Sonelokimab M-1095; ALX-0761; MSB-0010841 Phase 2 Clinical Ablynx Nv Psoriasis; Hidradenitis Suppurativa Details
DMT-310 DMT-310 Phase 2 Clinical Dermata Rosacea Details
Izokibep AFB-035; ABY-035; IMG-020; IMG020 Phase 3 Clinical Affibody Ab Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic; Hidradenitis Suppurativa; Uveitis; Plaque psoriasis Details
SSGJ-608 608; SSGJ-608 Phase 3 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Psoriasis; Plaque psoriasis Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap